MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI): auditor change — Maravai LifeSciences dismisses EY, appoints Deloitte; material weakness disclosed

MARAVAI LIFESCIENCES HOLDINGS, INC.

EY dismissed as auditor; Deloitte appointed effective July 16, 2025 for FY 2025.
EY's audit reports on financial statements for 2023 and 2024 were unqualified.
EY's internal control report for 2024 contained an adverse opinion citing material weaknesses in revenue/AR and goodwill impairment.
No disagreements on accounting principles or reportable events other than the internal control weakness.
Company did not consult Deloitte before the appointment; EY letter filed as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

MARAVAI LIFESCIENCES HOLDINGS, INC. engaged Deloitte & Touche LLP as its auditor.

Action: engagement
Auditor: Deloitte & Touche LLP

Exact text from the filing

(the “ Company ”) approved the appointment of Deloitte & Touche LLP (“ Deloitte ”) as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

MARAVAI LIFESCIENCES HOLDINGS, INC. dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: Deloitte & Touche LLP

Exact text from the filing

In addition, on the Approval Date, the Audit Committee approved the dismissal of Ernst & Young LLP (“ EY ”) as the Company’s independent registered public accounting firm.

View on SEC.gov

19 auditor changes filed in the last 30 days. Browse all auditor changes →

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001823239-25-000099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.